The FDA on Tuesday opened a path for new sunscreen actives by approving bemotrizinol — the first addition to the U.S. list of permissible sunscreen ingredients in more than 25 years. Clinically, the decision could expand broad-spectrum OTC options for adults and children 6 months and older, with use allowed at concentrations up to 6% and a U.S. launch expected in 2026.

The Move

• The federal health agency signed off on bemotrizinol for use in over-the-counter sunscreens after finding it met standards for UV protection with little irritation or skin absorption.

• The ingredient, long used in Europe and other markets, will initially be sold in the U.S. as Parsol Shield by DSM Nutritional Products.

• Other manufacturers can use the ingredient after an 18-month exclusivity period.

Why It Matters For Care

• For clinicians counseling on skin cancer prevention, the approval may eventually broaden sunscreen formulations available to patients who need better tolerability, cosmetic acceptability, or UVA/UVB coverage.

• The FDA said bemotrizinol is generally recognized as safe and effective for adults and children 6 months and older.

• Current patient guidance does not change now: recommend broad-spectrum sunscreen with SPF 15 or higher, plus protective clothing and sun avoidance during peak exposure.

Between The Lines

• FDA Commissioner Marty Makary said the agency has historically moved too slowly on sunscreen ingredients, leaving Americans with fewer options than consumers abroad.

• The move fits a broader FDA push to modernize regulation of nonprescription drugs and speed access to safe, effective consumer products.

• Politically, it gives the agency a visible consumer-health win in an area where U.S. regulation has lagged Europe despite longstanding demand from dermatology and industry.

What To Watch

• Whether DSM meets its expected 2026 launch timeline for Parsol Shield-containing products.

• How quickly other manufacturers move once the 18-month exclusivity window expires.

• Whether FDA uses the same pathway to clear additional new OTC sunscreen actives or other nonprescription drug ingredients.

Source: Fox News